{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Martin J Wildman, Alicia O’Cathain, Daniel Hind, Chin Maguire, Madelynne A Arden, Marlene Hutchings, Judy Bradley, Stephen J Walters, Pauline Whelan, John Ainsworth, Paul Tappenden, Iain Buchan, Rachel Elliott, Jon Nicholl, Stuart Elborn, Susan Michie, Laura Mandefield, Laura Sutton, Zhe Hui Hoo, Sarah J Drabble, Elizabeth Lumley, Daniel Beever, Aline Navega Biz, Anne Scott, Simon Waterhouse, Louisa Robinson, Mónica Hernández Alava & Alessandro Sasso.

Martin J Wildman ^1,2, Alicia O’Cathain ^2,*, Daniel Hind ³, Chin Maguire ³, Madelynne A Arden ⁴, Marlene Hutchings ¹, Judy Bradley ⁵, Stephen J Walters ², Pauline Whelan ⁶, John Ainsworth ⁶, Paul Tappenden ², Iain Buchan ^6,7, Rachel Elliott ⁸, Jon Nicholl ², Stuart Elborn ⁵, Susan Michie ⁹, Laura Mandefield ², Laura Sutton ², Zhe Hui Hoo ^1,2, Sarah J Drabble ², Elizabeth Lumley ², Daniel Beever ³, Aline Navega Biz ², Anne Scott ³, Simon Waterhouse ³, Louisa Robinson ³, Mónica Hernández Alava ², Alessandro Sasso ²

¹ Sheffield Adult Cystic Fibrosis Centre, Northern General Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
² School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
³ Clinical Trials Research Unit, University of Sheffield, Sheffield, UK
⁴ Centre for Behavioural Science and Applied Psychology, Sheffield Hallam University, Sheffield, UK
⁵ Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK
⁶ Health eResearch Centre, Division of Imaging, Informatics and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
⁷ Department of Public Health and Policy, Institute of Population Health Sciences, University of Liverpool, Liverpool, UK
⁸ Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
⁹ Centre for Behaviour Change, University College London, London, UK
^* Corresponding author Email: a.ocathain@sheffield.ac.uk

Declared competing interests of authors: Martin J Wildman reports funding from NHS England, PARI GmbH (Starnberg, Germany) and Koninklijke Philips N.V. (Amsterdam, the Netherlands) during the conduct of the study. His team received equipment and support for independent statistical advice to investigate the I-neb device (Koninklijke Philips N.V.) as a mechanism of detecting exacerbations. He received travel expenses to meet PARI GmbH in Munich to explain the CFHealthHub programme. His team has received funding for independent statistical advice to investigate the use of spirometric devices to understand lung function in the community and devices to support this study. The ACTif (Development and evaluation of an intervention to support Adherence to treatment in adults with Cystic Fibrosis) programme was supported by the NHS England Commissioning for Quality and Innovation (CQUIN) payment framework [funding identifier IM2 Cystic Fibrosis Patient Adherence (Adult)]. Alicia O’Cathain was a member of a subpanel for the National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) programme (2007–17). Daniel Hind reports grants from the NIHR (10/57/46, 12/28/05, 12/144/04, 13/24/03, 15/178/09, 17/17/02, 17/72/02, NIHR127454 and 17/136/10), NHS England and Koninklijke Philips N.V. during the conduct of the study outside the submitted work. He was a member of the following committees during the project: NIHR Research for Patient Benefit, Yorks and North East Regional Advisory Committee (2016–20) and NIHR Health Technology Assessment (HTA) Clinical Evaluation and Trials Funding Committee (2019–20). Stephen J Walters reports grants from the Department of Health and Social Care, NIHR, Medical Research Council (MRC) and National Institute for Health and Care Excellence (NICE); personal fees from book royalties; personal fees from external examining; and an NIHR Senior Investigator award, outside the submitted work. He was a member of the following during the project: NIHR HTA Clinical Trials and Evaluation Committee (2011–17), NIHR HTA Commissioning Strategy Group (2012–17), NIHR PGfAR Committee (2020) and NIHR Pre-doctoral Fellowship Selection Committee (2019–20). Pauline Whelan reports that the University of Manchester software team received funds from PARI GmbH outside the submitted work. She is a director of Affigo C.I.C. (Altrincham, UK), a Manchester-based community interest company, which comprises a team of clinicians, academics and software engineers who work closely with mental health service users to develop innovative digital technologies. Affigo C.I.C. has not been involved in this project or publication. Pauline Whelan is the owner/director of Prism Life Ltd (Leeds, UK), a small research and software consultancy company. Prism Life Ltd has had no involvement in this work. John Ainsworth reports funding from PARI GmbH outside the submitted work. He is director of Affigo C.I.C. Iain Buchan reports grants from the MRC during the conduct of the study, personal fees and other funding from AstraZeneca plc (Cambridge, UK), and personal fees and other funding from Microsoft Corporation (Redmond, WA, USA), outside the submitted work. Stuart Elborn reports grants from the Innovative Medicines Initiative, Seventh Framework Programme, European Commission, the MRC and the United Kingdom Bronchiectasis Registry (BRONCH-UK) during the conduct of the study. Zhe Hui Hoo reports other funding from NHS England and PARI GmbH during the conduct of the study.